Tetrabenazine for involuntary movement disorders.
The use of tetrabenazine to treat the movement disorder of Huntington's chorea and other dyskinesias is described. Tetrabenazine produced moderate to marked improvement in the movement disorder in 79% of a series of 40 Australian patients. The most commonly reported side effects were depression, drowsiness and Parkinsonism.
D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy*; D013747:Tetrabenazine / Q000009:adverse effects / Q000627:therapeutic use*
D013747:Tetrabenazine